OPKO Health/$OPK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About OPKO Health
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Ticker
$OPK
Sector
Primary listing
Industry
Health Care Providers & Services
Headquarters
Employees
2,997
ISIN
US68375N1037
Website
OPKO Health Metrics
BasicAdvanced
$1.1B
-
-$0.06
1.42
-
Price and volume
Market cap
$1.1B
Beta
1.42
52-week high
$2.04
52-week low
$1.21
Average daily volume
3.2M
Financial strength
Current ratio
2.493
Quick ratio
1.473
Long term debt to equity
24.625
Total debt to equity
34.025
Interest coverage (TTM)
-5.67%
Profitability
EBITDA (TTM)
-173.411
Gross margin (TTM)
15.23%
Net profit margin (TTM)
-5.66%
Operating margin (TTM)
-39.06%
Effective tax rate (TTM)
-6,628.28%
Revenue per employee (TTM)
$230,000
Management effectiveness
Return on assets (TTM)
-8.20%
Return on equity (TTM)
-3.04%
Valuation
Price to revenue (TTM)
1.352
Price to book
0.7
Price to tangible book (TTM)
1.43
Price to free cash flow (TTM)
-4.518
Free cash flow yield (TTM)
-22.13%
Free cash flow per share (TTM)
-30.10%
Growth
Revenue change (TTM)
-13.78%
Earnings per share change (TTM)
-83.30%
3-year revenue growth (CAGR)
-23.81%
10-year revenue growth (CAGR)
21.43%
3-year earnings per share growth (CAGR)
-31.70%
10-year earnings per share growth (CAGR)
-20.54%
What the Analysts think about OPKO Health
Analyst ratings (Buy, Hold, Sell) for OPKO Health stock.
Bulls say / Bears say
OPKO Health's collaboration with Entera Bio to develop an oral GLP-1/glucagon tablet for obesity treatment positions the company in the growing obesity drug market. (stocktitan.net)
The $225 million sale of BioReference's oncology and related clinical testing assets to Labcorp is expected to streamline operations and strengthen OPKO's financial position. (nasdaq.com)
OPKO Health's $100 million increase to its share repurchase program demonstrates confidence in the company's future prospects and commitment to enhancing shareholder value. (stocktitan.net)
OPKO Health reported a net loss of $67.6 million in Q1 2025, indicating ongoing financial challenges. (stocktitan.net)
StockNews.com downgraded OPKO Health's rating to 'sell' in December 2024, reflecting concerns about the company's performance. (etfdailynews.com)
The sale of BioReference's assets to Labcorp may lead to reduced revenue streams, potentially impacting OPKO Health's financial stability. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
OPKO Health Financial Performance
Revenues and expenses
OPKO Health Earnings Performance
Company profitability
OPKO Health News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for OPKO Health stock?
OPKO Health (OPK) has a market cap of $1.1B as of July 11, 2025.
What is the P/E ratio for OPKO Health stock?
The price to earnings (P/E) ratio for OPKO Health (OPK) stock is 0 as of July 11, 2025.
Does OPKO Health stock pay dividends?
No, OPKO Health (OPK) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next OPKO Health dividend payment date?
OPKO Health (OPK) stock does not pay dividends to its shareholders.
What is the beta indicator for OPKO Health?
OPKO Health (OPK) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.